ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC) is aggressive and presents unique clinical challenges and limited treatment options due to the absence of the targetable estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) [8].